| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Eltrombopag olamine (JAN/USAN); Promacta (TN) | ||||||
| Product | PROMACTA (Novartis Pharmaceuticals Corporation) | ||||||
| Formula | C25H22N4O4. (C2H7NO)2 | ||||||
| Exact mass | 564.2696 | ||||||
| Mol weight | 564.6327 | ||||||
| Structure |  | ||||||
| Remark |
| ||||||
| Efficacy | Antithrombocytopenia, Thrombopoietin receptor agonist | ||||||
| Disease | Chronic immune thrombocytopenia [DS:H01240] Aplastic anemia [DS:H01132] | ||||||
| Comment | Treatment of chemotherapy-induced thrombocytopenia and treatment of immune thrombocytopenic purpura | ||||||
| Target | MPL (TPOR, CD110) [HSA:4352] [KO:K05082] | ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] B BLOOD AND BLOOD FORMING ORGANS B02 ANTIHEMORRHAGICS B02B VITAMIN K AND OTHER HEMOSTATICS B02BX Other systemic hemostatics B02BX05 Eltrombopag D03978 Eltrombopag olamine (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Blood Products and Modifiers Blood Products and Modifiers, Other Blood Products and Modifiers, Micellaneous Eltrombopag Olamine D03978 Eltrombopag olamine (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 39 Other agents affecting metabolism 399 Miscellaneous 3999 Others D03978 Eltrombopag olamine (JAN/USAN) Target-based classification of drugs [BR:br08310] Cytokines and receptors Cytokine receptors CSF and other factor receptors MPL (TPOR, CD110) D03978 Eltrombopag olamine (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D03978 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D03978 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D03978 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D03978 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D03978 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 41 1 N1a N 35.8702 -19.1003 2 C1b C 37.0869 -18.3978 3 C1b C 38.3036 -19.1003 4 O1a O 39.5203 -18.3978 5 N2x N 27.1600 -16.3800 6 C2y C 28.5600 -16.3800 7 C2y C 28.9926 -15.0485 8 C5x C 27.8600 -14.2256 9 N1y N 26.7274 -15.0485 10 O5x O 27.8600 -12.8100 11 C8y C 25.5149 -14.3485 12 C8x C 24.3025 -15.0485 13 N1b N 31.4175 -15.0485 14 N2b N 30.2051 -14.3485 15 C1a C 29.3829 -17.5126 16 C8x C 25.5149 -12.9485 17 C8x C 24.3025 -12.2485 18 C8y C 23.0901 -12.9485 19 C8y C 23.0901 -14.3485 20 C8y C 32.6299 -14.3485 21 C1a C 21.8845 -15.0446 22 C1a C 21.8857 -12.2532 23 C8y C 33.8355 -15.0446 24 C8y C 35.0480 -14.3446 25 C8x C 35.0480 -12.9446 26 C8x C 33.8424 -12.2485 27 C8x C 32.6300 -12.9485 28 O1a O 33.8356 -16.4498 29 C8y C 36.2792 -15.0556 30 C8x C 36.2790 -16.4499 31 C8x C 37.4913 -17.1501 32 C8x C 38.7038 -16.4502 33 C8y C 38.7040 -15.0560 34 C8x C 37.4917 -14.3558 35 C6a C 39.9237 -14.3521 36 O6a O 41.1172 -15.0416 37 O6a O 39.9240 -12.9502 38 N1a N 35.8702 -19.1003 39 C1b C 37.0869 -18.3978 40 C1b C 38.3036 -19.1003 41 O1a O 39.5203 -18.3978 BOND 42 1 5 6 2 2 6 7 1 3 7 8 1 4 8 9 1 5 5 9 1 6 8 10 2 7 9 11 1 8 11 12 1 9 13 14 1 10 7 14 2 11 6 15 1 12 11 16 2 13 16 17 1 14 17 18 2 15 18 19 1 16 12 19 2 17 13 20 1 18 19 21 1 19 18 22 1 20 20 23 2 21 23 24 1 22 24 25 2 23 25 26 1 24 26 27 2 25 20 27 1 26 23 28 1 27 24 29 1 28 29 30 2 29 30 31 1 30 31 32 2 31 32 33 1 32 33 34 2 33 29 34 1 34 33 35 1 35 35 36 1 36 35 37 2 37 1 2 1 38 2 3 1 39 3 4 1 40 38 39 1 41 39 40 1 42 40 41 1 BRACKET 1 33.8800 -19.8800 33.8800 -17.6400 1 40.8100 -17.6400 40.8100 -19.8800 1 2 ORIGINAL 1 1 2 3 4 REPEAT 1 38 39 40 41 |